...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cancer Research and Therapeutics >Concurrent computed tomography-guided radioactive iodine-125 seeds percutaneous interstitial implantation and chemotherapy for treatment of cervical lymph node metastases
【24h】

Concurrent computed tomography-guided radioactive iodine-125 seeds percutaneous interstitial implantation and chemotherapy for treatment of cervical lymph node metastases

机译：并行计算机体层摄影术指导的放射性碘125种子经皮间质植入和化学疗法治疗宫颈淋巴结转移

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: The study aimed to evaluate the effect of concurrent computed tomography (CT)-guided percutaneous interstitial implantation of iodine-125 (125I) seeds and chemotherapy on cervical lymph nodes metastasis. Methods: The prospective randomized study included 82 cases with cervical lymph nodes metastasis who were admitted to our hospital from January 2010 to June 2012. All the subjects were randomly divided into the concurrent 125I implantation and chemotherapy group (n = 48) and chemotherapy-only group (n = 34) according to the treatment strategy. The concurrent 125I implantation and chemotherapy group was treated with CT-guided 125I seeds implantation and routine chemotherapy. The routine chemotherapy included paclitaxel and cisplatin. Patients were followed up for 6 months. Results: In the concurrent 125I implantation and chemotherapy group, overall response rate (complete response [CR] + partial response [PR]) was 82.61% and 85.51% at 2 and 6 months posttreatment, respectively. The longest diameter of CR and PR lymph nodes was markedly decreased after treatment (P 125I implantation and chemotherapy group than that of chemotherapy-only group (4.17% vs. 17.64%; P Conclusion: Concurrent CT-guided 125I seeds implantation and chemotherapy is superior to routine chemotherapy in efficacy, safety, and pain relief in patients with cervical lymph nodes metastasis.
机译：目的：该研究旨在评估同时行计算机体层摄影术（CT）引导的碘125（125I）种子经皮间质植入和化疗对宫颈淋巴结转移的影响。方法：前瞻性随机研究包括2010年1月至2012年6月入院的82例颈淋巴结转移的患者。所有受试者均随机分为同期125I植入和化疗组（n = 48）和仅接受化疗根据治疗策略分组（n = 34）。同时进行的125I植入和化疗组接受CT引导的125I种子植入和常规化疗。常规化疗包括紫杉醇和顺铂。对患者进行了6个月的随访。结果：在并发的125I植入和化疗组中，治疗后2个月和6个月的总缓解率（完全缓解[CR] +部分缓解[PR]）分别为82.61％和85.51％。治疗后CR和PR淋巴结的最长直径明显减少（P 125I植入和化疗组比单纯化疗组（4.17％vs. 17.64％; P结论）：CT引导下同时进行125I种子植入和化疗效果更好常规化疗在宫颈淋巴结转移患者中的有效性，安全性和疼痛缓解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号